blood plasma News
-
Infants at greater risk from food packaging chemical
Bisphenol A (BPA) is a commonly used chemical in the manufacture of food packaging and there are concerns over its safety, particularly for young children. A recent study suggests that there is a five times greater BPA plasma concentration in babies aged between three and six months compared with adults. In 2008, both Canada and the USA raised concerns over the possible harmful effects of BPA on ...
-
Selfdiagnostics SARS-CoV-2 IgM/IgG Antibody Assay Kit is a rapid, accurate and straightforward point-of-care test kit that qualitatively detects IgM and IgG antibodies against the virus that causes COVID-19.
The test detects specific SARS CoV2 IgG and IgM antibodies in the blood in response to a coronavirus infection. The detection of antibodies can be used to identify those who have already had contact with the virus. IgG may remain elevated for up to several months and possibly years, which could help determine who has been exposed to the coronavirus, even if a person did not exhibit any symptoms ...
-
SAGA Diagnostics enters into Development Agreement with AstraZeneca
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR ...
-
AptaMatrix, Inc. Receives a NIH Small Business Innovation Research Phase II Award
AptaMatrix, Inc., a Syracuse-based biotech company focused on developing aptamer-based technologies for diagnostic applications, announces that it has been awarded a $2M Phase II Small Business Innovation Research (SBIR) grant by the National Institute of General Medical Sciences (NIGMS) institute of the National Institutes of Health (NIH). The Phase II award will allow AptaMatrix to develop and ...
-
SAGA expands research collaboration with University College London Cancer Institute
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute. Last year, SAGA and UCL entered into a research collaboration on a limited number of ...
-
DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Diagnosis and Monitoring of Rett Syndrome and Other Neurodevelopmental Diseases
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/028,206 entitled "Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders." The patent covers the ...
By DiamiR
-
GFL employees participate in plasma donation drive
GFL recently partnered with Canadian Blood Services to organize a plasma donation drive in honor of the newly opened plasma donor center near GFL’s Vaughan, Ontario, head office. GFL employees donated their plasma with the goal of helping patients in local hospitals who require this life-saving component in blood. “It was amazing to see our team come together to support the ...
-
DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of Circulating Brain-Enriched microRNA Biomarkers for Monitoring of Brain Aging; Provides Update on Its Patent Portfolio
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/044,279 entitled "miRNA-based methods for detecting and monitoring aging." The patent covers the use of methods developed by DiamiR based ...
By DiamiR
-
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders. The study was ...
By Cingulate
-
New frontiers with advanced gas analyzers for medical applications
ETG-LGR instruments provide fast measurements of isotopic ratios (δ2H, δ17O, δ18O, δ13C) in blood, urine, plasma, saliva and breath. No longer limited by time consuming sample preparation, equilibration, or pre-concentration processes, fast and precise measurements may be obtained by untrained personnel in real time at a fraction of the cost. For example, traditional ...
-
Creative Proteomics Lipidomics Upgrades Its Medium-Chain and Long-Chain Fatty Acids Analysis Service
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomic research services for biomedical institutions as well as biotechnological and pharmaceutical companies. The company has recently upgraded its medium-chain and long-chain fatty acid analysis service. This service can provide reflections on lipid metabolism, glucose ...
-
Anxin medicine introduces you to the secrets of medical polymer materials
Medical polymer materials for the first time into the line of sight of people in 1949, is the first published the prospect of medical polymer materials, for the first time introduced the use of poly (methyl methacrylate as a person's skull, joint and femoral, using polyamide as the clinical application of surgical suture, since then, usher in rapid development of medical polymer materials, is ...
-
Two Research Studies Bolster Method That C2N’s PrecivityAD Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses
Two recent studies demonstrated that the scientific method that serves as the basis for C2N Diagnostics’ PrecivityAD™ blood test scored best compared to others assays in their respective ability to identify amyloid plaque. The C2N Diagnostics PrecivityAD™ blood test that clinicians use to aid in diagnosing Alzheimer’s disease is underpinned by the liquid ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Grifols and Shanghai RAAS close their strategic alliance in China
Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS) Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales ...
-
BSI group America Inc. Announces specialized regulatory training courses for the healthcare industry
BSI Group America Inc., a leading provider of total solutions for certification and standards announces the launch of Specialized Regulatory Training courses targeted specifically for the medical device industry. Available on-site, these Specialized Regulatory Courses reflect requirements of the latest amendments to the Medical Device Directive enabling attendees to comply efficiently with ...
-
Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19
Grifols has adopted a number of measures since the onset of the pandemic in order to respond to the needs of its stakeholders. The company continually monitors the progression of COVID-19, analyzing and evaluating its potential impact on its workforce and operations to guarantee minimal delays or interruptions in our operations as Grifols’ products and services are essential for patients ...
-
Daxor Announces Key Milestones Achieved for Multicenter Bva-100® Study In Hospitalized Patients With Covid-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake ...
-
Nova Blood Gas Analyzers Add Important New Test: Mean Corpuscular Hemoglobin Concentration (MCHC)
Waltham, MA - Nova Biomedical announces the addition of another important critical care parameter to its Stat Profile Prime Plus blood gas analyzer—the ability to rapidly calculate and report mean corpuscular hemoglobin concentration (MCHC). MCHC is a measure of the hemoglobin concentration in a given volume of packed red blood cells. MCHC, along with measured hemoglobin and ...
-
Longenesis announces Curator platform for privacy-preserving data use for COVID-19 research
Longenesis - a digital health startup aiming towards the acceleration of the biomedical research pipeline worldwide, announced a release of its product Curator. It is a platform where clinical institutions and patient organizations are connected in consortiums with potential collaboration partners and study sponsors to initiate further cooperation. The main difference between existing solutions - ...
By Longenesis
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you